Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

June 10, 2014 updated by: Boehringer Ingelheim

Pramipexole Special Survey on Long-Term Use

The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

1645

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Agano, Japan
        • Boehringer Ingelheim Investigational Site
      • Aizuwakamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Akashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site
      • Asahikawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Asakura, Japan
        • Boehringer Ingelheim Investigational Site
      • Ayagawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Azumino, Japan
        • Boehringer Ingelheim Investigational Site
      • Bando, Japan
        • Boehringer Ingelheim Investigational Site
      • Beppu, Japan
        • Boehringer Ingelheim Investigational Site
      • Bihoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Chiba, Japan
        • Boehringer Ingelheim Investigational Site
      • Chikusei, Japan
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japan
        • Boehringer Ingelheim Investigational Site
      • Date, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebina, Japan
        • Boehringer Ingelheim Investigational Site
      • Eiheiji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujieda, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujiyoshida, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukui, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Geisei, Japan
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ginowan, Japan
        • Boehringer Ingelheim Investigational Site
      • Hachinohe, Japan
        • Boehringer Ingelheim Investigational Site
      • Hadano, Japan
        • Boehringer Ingelheim Investigational Site
      • Haebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Hagahama, Japan
        • Boehringer Ingelheim Investigational Site
      • Hakodate, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamada, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashimurayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiyamato, Japan
        • Boehringer Ingelheim Investigational Site
      • Himeji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiratsuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiroshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Hita, Japan
        • Boehringer Ingelheim Investigational Site
      • Hofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichikikushikino, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikeda, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikoma, Japan
        • Boehringer Ingelheim Investigational Site
      • Ina, Japan
        • Boehringer Ingelheim Investigational Site
      • Inazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Inba, Japan
        • Boehringer Ingelheim Investigational Site
      • Inuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Isezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Itoigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japan
        • Boehringer Ingelheim Investigational Site
      • Joetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kahoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Kajiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakegawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamisu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kannonji, Japan
        • Boehringer Ingelheim Investigational Site
      • Karatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kasukabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kato, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawagoe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawatana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kikugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kirishima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kitakyushu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyotake, Japan
        • Boehringer Ingelheim Investigational Site
      • Kizugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kochi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kodaira, Japan
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Koga, Japan
        • Boehringer Ingelheim Investigational Site
      • Kokubunji, Japan
        • Boehringer Ingelheim Investigational Site
      • Komae, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Komoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurashiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurayoshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kure, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurume, Japan
        • Boehringer Ingelheim Investigational Site
      • Kushiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Kutchan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kuwana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyonan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Maibara, Japan
        • Boehringer Ingelheim Investigational Site
      • Maizuru, Japan
        • Boehringer Ingelheim Investigational Site
      • Marugame, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuda, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsue, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Miki, Japan
        • Boehringer Ingelheim Investigational Site
      • Minakami, Japan
        • Boehringer Ingelheim Investigational Site
      • Minamata, Japan
        • Boehringer Ingelheim Investigational Site
      • Minobu, Japan
        • Boehringer Ingelheim Investigational Site
      • Misashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Mito, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyakonojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Mooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriya, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Muroran, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagakute, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nangoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site
      • Narita, Japan
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japan
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japan
        • Boehringer Ingelheim Investigational Site
      • Niigata, Japan
        • Boehringer Ingelheim Investigational Site
      • Niihama, Japan
        • Boehringer Ingelheim Investigational Site
      • Nikko, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishigo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishio, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nobeoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Noboribetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Numazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Obama, Japan
        • Boehringer Ingelheim Investigational Site
      • Obihiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Odate, Japan
        • Boehringer Ingelheim Investigational Site
      • Odawara, Japan
        • Boehringer Ingelheim Investigational Site
      • Ofunato, Japan
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Ohzu, Japan
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japan
        • Boehringer Ingelheim Investigational Site
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site
      • Ojiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Okawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Omaezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Omura, Japan
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japan
        • Boehringer Ingelheim Investigational Site
      • Onga, Japan
        • Boehringer Ingelheim Investigational Site
      • Onojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Onomichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ozu, Japan
        • Boehringer Ingelheim Investigational Site
      • Sado, Japan
        • Boehringer Ingelheim Investigational Site
      • Saga, Japan
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakaide, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakata, Japan
        • Boehringer Ingelheim Investigational Site
      • Saku, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanjo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sano, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanyoonoda, Japan
        • Boehringer Ingelheim Investigational Site
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sasebo, Japan
        • Boehringer Ingelheim Investigational Site
      • Seijo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimabara, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimonoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site
      • Shingu, Japan
        • Boehringer Ingelheim Investigational Site
      • Shinshiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Shunan, Japan
        • Boehringer Ingelheim Investigational Site
      • Soo, Japan
        • Boehringer Ingelheim Investigational Site
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site
      • Tajimi, Japan
        • Boehringer Ingelheim Investigational Site
      • Takamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Takanabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasago, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takatsuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takehara, Japan
        • Boehringer Ingelheim Investigational Site
      • Toda, Japan
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Adachi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chiyoda-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Edogawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Itabashi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Katsushika-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Kita-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Minayo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nakano-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjuku-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Suginami-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomakomai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomiai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tondabayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Toon, Japan
        • Boehringer Ingelheim Investigational Site
      • Toride, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyoake, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsubata, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuchiura, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsukuba, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuruoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japan
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japan
        • Boehringer Ingelheim Investigational Site
      • Uji, Japan
        • Boehringer Ingelheim Investigational Site
      • Ujo, Japan
        • Boehringer Ingelheim Investigational Site
      • Urayasu, Japan
        • Boehringer Ingelheim Investigational Site
      • Uruma, Japan
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Wakayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamagata, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamaguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Yanai, Japan
        • Boehringer Ingelheim Investigational Site
      • Yao, Japan
        • Boehringer Ingelheim Investigational Site
      • Yashiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokkaichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokote, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Yufu, Japan
        • Boehringer Ingelheim Investigational Site
      • Zama, Japan
        • Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Parkinson's disease patients in daily clinical settings

Description

Inclusion Criteria:

Patients with Parkinson's disease

Exclusion Criteria:

Patients should have been treated according to the Japanese insert slip

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events
Time Frame: during 18 months
The aim of this Post Marketing Surveillance (PMS) was to obtain long-term safety data with treatment of pramipexole in Parkinson's disease (PD) patients. Therefore these items were considered as a safety evaluation.
during 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Global Impression of Improvement
Time Frame: 18 months
Investigators evaluation of the PD symptoms on a rating scale of 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
18 months
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Time Frame: Baseline and at 18 months (or at the time of discontinuation)
Motor examination is assessed by 27 questionnaire items in UPDRS Part III section. Each item is scored from 0 (best) to 4 (worst), and the total score of UPDRS Part III is from 0 (best) to 108 (worst). A decrease in the score means improvement.
Baseline and at 18 months (or at the time of discontinuation)
Change From Baseline in Modified Hoehn & Yahr Rating Scale
Time Frame: Baseline and at 18 months (or at the time of discontinuation)
A severity of PD symptom are assessed by Modified Hoehn & Yahr rating scale. This scale consist of 10 levels including additional evaluation levels defined in Japan. Ten levels are described by 0 (best), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 (worst).
Baseline and at 18 months (or at the time of discontinuation)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2004

Primary Completion (Actual)

March 1, 2009

Study Registration Dates

First Submitted

January 31, 2008

First Submitted That Met QC Criteria

February 13, 2008

First Posted (Estimate)

February 14, 2008

Study Record Updates

Last Update Posted (Estimate)

July 11, 2014

Last Update Submitted That Met QC Criteria

June 10, 2014

Last Verified

June 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Subscribe